Guardant Health had its Relative Strength (RS) Rating upgraded from 86 to 92 Friday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an 80 or higher RS Rating at the beginning of a new price run.
Guardant Health has moved more than 5% past a 50.54 entry in a second-stage cup with handle, meaning it's now out of a proper buy zone. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Guardant Health posted 0% earnings growth in its most recent report. Revenue gains came in at 31%.
Guardant Health earns the No. 12 rank among its peers in the Medical-Services industry group. GeneDx Holdings, Hims & Hers Health and Stevanato Group are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
